FIGURE 1.
Correlation of ERCC5 (XPG) expression in tumors with patient survival (A) Kaplan–Meier (KM) plot of patients with or without ERCC5 mutations in their tumors (all cancers), as a function of patient survival after diagnosis. Patients with ERCC5 mutations in their tumors are at higher risk. Data are in Supplementary Table S1. (B) Prognostic risk for tumors with low ERCC5, XPA, or XPC expression. KM plots of patients with tumors that had ERCC5, XPA, or XPC mRNA expression levels above and below the mean. Plots are shown for the three cancers with significant prognostic risk based on ERCC5 expression: mesothelioma (MESO), low grade glioma (LGG), and bladder urothelial carcinoma (BLCA). Only low XPA expression in mesothelioma showed significant risk. Data are in Supplementary Tables S2, S3. (C) Benjamini–Hochberg-corrected p-values and most significant Gene Ontology (GO) terms for gene enrichment analysis of genes identified to yield KM logrank p-values <1 × 10−4 when expressed at low (below or equal to the mean, blue) or high (above the mean, orange) levels in LGG patients. Data are in Supplementary Table S4.